Hsiao noted the options are adalimumab, a tumor necrosis factor α inhibitor; secukinumab, an IL-17A inhibitor; and ...
She described the patient consult as the starting point for aesthetic care. It covers the patient’s history, motivation for seeking treatment, prior aesthetic procedures, keloid history, and herpes ...
Trotter said dermatologists should pay attention to locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results